

**GEORGIA BOARD OF PHARMACY**  
**Board Meeting**  
**2 Peachtree Street, NW, 5<sup>th</sup> Floor**  
**Atlanta, GA 30303**  
**April 18, 2018**  
**9:00 a.m.**

**The following Board members were present:**

Chris Jones, President  
Vicki Arnold  
Jim Bracewell  
Mike Faulk  
Lisa Harris  
Laird Miller

**Staff present:**

Tanja Battle, Executive Director  
Dennis Troughton, Director, GDNA  
Ronnie Higgins, Deputy Director, GDNA  
Carla Leary, Business Ops Manager, GDNA  
Max Changus, Assistant Attorney General  
Kimberly Emm, Attorney  
Brandi Howell, Business Support Analyst I

**Visitors:**

John Rocchio, CVS Health  
Leigh Carpenter, Hemophilia of Georgia  
Gary Meyer, Integrity Compounding  
Stephen Snow, BSC  
Rena Estep, Walgreens  
Adam Schnepf, Walgreens  
Beth Jarrett, Walmart  
Bethany Sherrer, MAG  
Karla Kiriako, Sanofi US  
Mike Chavez, Publix  
Amanda Roberson, ElderCare  
Jessica Kilcoyne, Velano Vascular  
Ryan Loke, McKesson  
Lea Bonner, Mercer University  
Hillary Thrower, Emory  
Amy Krieg, GHA  
Helen Sloat, Kaiser Permanente, Hemophilia of GA  
Cecil Cordle, CVS Health  
Robert Borsom, CVS Health  
Mitchell Tuttle, UGA/CVS  
Diane Sanders, Kaiser Permanente  
Nichelle Sims, Hemophilia of GA

**Open Session**

President Jones established that a quorum was present and called the meeting to order at 9:09 a.m.

**Approval of Minutes**

Jim Bracewell made a motion to approve the Public Session minutes from the March 7, 2018 meeting. Mike Faulk seconded and the Board voted unanimously in favor of the motion.

Jim Bracewell made a motion to approve the Executive Session minutes from the March 7, 2018 meeting. Mike Faulk seconded and the Board voted unanimously in favor of the motion.

### **Report of Licenses Issued**

Vicki Arnold made a motion to ratify the list of licenses issued. Lisa Harris seconded and the Board voted unanimously in favor of the motion.

### **Petitions for Rule Variance or Waiver**

Mike Faulk made a motion to deny a rule variance petition from Advanced Diabetes Supply, PHNR001354. Laird Miller seconded and the Board voted unanimously in favor of the motion.

Mike Faulk made a motion to grant a rule waiver petition from Rigel Pharmaceuticals, Inc. Lisa Harris seconded and the Board voted unanimously in favor of the motion.

Vicki Arnold made a motion to grant a rule waiver petition from Aclaris Therapeutics, Inc. Jim Bracewell seconded and the Board voted unanimously in favor of the motion.

Lisa Harris made a motion to grant a rule waiver petition from Biocompatibles, Inc. Vicki Arnold seconded and the Board voted unanimously in favor of the motion.

Lisa Harris made a motion to grant a rule waiver petition from Biocompatibles, Inc. Vicki Arnold seconded and the Board voted unanimously in favor of the motion.

Vicki Arnold made a motion to grant a rule waiver petition from BTG International, Inc., PHMA000303. Lisa Harris seconded and the Board voted unanimously in favor of the motion.

Vicki Arnold made a motion to grant a rule waiver petition from BTG International, Inc., PHWH003014. Lisa Harris seconded and the Board voted unanimously in favor of the motion.

Mike Faulk made a motion to grant a rule waiver petition from CR Bard, Inc. Jim Bracewell seconded and the Board voted unanimously in favor of the motion.

Mike Faulk made a motion to grant a rule waiver petition from Analog Pharma, PHWH003469. Vicki Arnold seconded and the Board voted unanimously in favor of the motion.

Lisa Harris made a motion to grant a rule waiver petition from scPharmaceuticals, Inc. Mike Faulk seconded and the Board voted unanimously in favor of the motion.

Lisa Harris made a motion to deny a rule variance petition from Emily D. Black. Mike Faulk seconded and the Board voted unanimously in favor of the motion.

### **Correspondence from Sue Spohn, Gemco Medical**

The Board considered this correspondence requesting clarification regarding Chapter 480-7B Durable Medical Equipment Suppliers. Mike Faulk made a motion to refer this correspondence to the Department of Law for review and response. Jim Bracewell seconded and the Board voted unanimously in favor of the motion.

### **Correspondence from Jeremy Alexander**

The Board considered this correspondence asking whether certain employees or contractors of a durable medical equipment supplier may provide remote instruction to residents of Georgia regarding certain respiratory care products; and whether the supplier is permitted to ship such products directly to patients.

Mike Faulk made a motion to direct staff to respond by stating that someone, in person, would need to instruct the patient on product use. Laird Miller seconded and the Board voted unanimously in favor of the motion.

#### **Correspondence from Carla Jarman**

The Board considered this correspondence requesting clarification regarding Rule 480-15-.13 and what is considered allowable personnel in a retail pharmacy. Jim Bracewell made a motion to direct staff to work with Director Troughton to clarify this information under the FAQ section on the Board's website. Laird Miller seconded and the Board voted unanimously in favor of the motion. In the same motion, the Board directed Ms. Emm to respond to Ms. Jarman regarding "other pharmacy personnel."

#### **Correspondence from Walter Williams, Piedmont**

The Board considered this correspondence regarding a hospital that is requesting to move its infusion center to a building separate from the hospital building located across the parking lot from its emergency room, but still on campus well within 250 yards. Mike Faulk made a motion to direct GDNA to conduct an inspection and report back to the Board. Lisa Harris seconded and the Board voted unanimously in favor of the motion.

#### **Correspondence from N. Lois Adams, HHCS**

The Board considered this correspondence requesting an advisory opinion as to whether or not two commonly owned and managed pharmacies located at the same physical address can lawfully provide pharmacy coverage for one another in Georgia. Mike Faulk made a motion to table this correspondence and direct staff to request additional information. Vicki Arnold seconded and the Board voted unanimously in favor of the motion.

#### **Question from Linda Chapman**

The Board discussed correspondence received from Ms. Chapman. Ms. Chapman's first concern is regarding high dollar medication. Ms. Chapman has a client that passed away from breast cancer and the family wants to donate the unused medications, which can cost around \$14,000 for a one month supply. Ms. Chapman is requesting the Board's perspective before speaking to the General Assembly about possible law changes or exceptions. The second concern is regarding DEA Take Back Days. Ms. Chapman stated there are no drop off locations in Sandy Springs or Buckhead. She stated the Board needs to have more DEA Take Back Days and these events need to be publicized by the Board.

Mike Faulk made a motion to direct staff to respond to Ms. Chapman's first concern by stating the family would be required to follow the Repository Law, O.C.G.A. § 31-8-300 through 31-8-304, also addressed in the Rules of the Department of Public Health Chapter 511-5-12. Additionally, if Ms. Chapman is interested in speaking to the General Assembly about legislative changes, the concern of the Board is the condition of the drugs, how they are stored, etc.

In response to Ms. Chapman's second concern regarding DEA Take Back Days, the Board directed staff to post information on the website regarding such. Jim Bracewell seconded and the Board voted unanimously in favor of the motion.

#### **Correspondence from Shali Reynolds**

The Board considered this correspondence requesting clarification regarding registered nurses and paramedics providing in home intravenous infusions to clients. Mike Faulk made a motion to direct staff to respond to Ms. Reynolds by stating that she needs to direct her inquiry to the Georgia Composite Medical Board, Georgia Board of Nursing and the Department of Public Health. Jim Bracewell seconded and the Board voted unanimously in favor of the motion.

### **Correspondences from Cathy Medeiros**

The Board considered this first correspondence from Ms. Medeiros requesting a letter stating Georgia does not require a license for device distribution. Mike Faulk made a motion to direct staff to respond by stating if the device requires an order, then the supplier is required to obtain a wholesaler license. Laird Miller seconded and the Board voted unanimously in favor of the motion.

The Board considered a second correspondence from Ms. Medeiros asking for confirmation that a Georgia license will not be required to ship the Carelink Monitor to Georgia patients. Vicki Arnold made a motion to respond by stating that if they are billing a third party, then they will need to obtain a DME license. Lisa Harris seconded and the Board voted unanimously in favor of the motion.

### **Correspondence from Aimee Schan**

The Board considered this correspondence containing questions pertaining to concierge medicine, IV hydration, midwives, and mobile MRI. Mike Faulk made a motion to direct staff to inform Ms. Schan her inquiry needs to be directed to the Georgia Composite Medical Board and the Georgia Board of Nursing. Lisa Harris seconded and the Board voted unanimously in favor of the motion.

### **Correspondence from Bob Warnock**

The Board recommended tabling this correspondence for the May meeting.

### **Correspondence from Stephen Snow**

The Board considered this correspondence regarding a request to strike Rule 480-16-.02(3) Receipt of Prescription Drug Order by a Non-Pharmacy. Mr. Snow was present at the meeting and spoke to the Board regarding his request. Mr. Snow explained that the Board recently met with Encompass Rx concerning its request to waive the written patient authorization for the pharmacy to deliver to the physician. The pharmacy's request and the Board's response have caused significant concerns among pharmacists and physicians alike with respect to the propriety of the patient authorization requirement itself. Mr. Snow stated that he recently spoke with the Georgia Composite Medical Board regarding this issue and the Board supports their position. He stated it is impossible or impractical to obtain that waiver beforehand. He stated it is impractical if the doctor issues the prescription without the patient being present. The continuity of patient care becomes jeopardized by that requirement. It forces the doctor to choose between patient care and violating a rule. Mr. Miller asked if the rule is being interpreted that it has to be for each prescription? Mr. Snow responded that his understanding was that a blanket waiver was not warranted and it should be prescription specific. Mr. Miller stated that creams and lotions are a problem. He added that he understands that there can be legitimate concerns; however, he does not see any point in requiring a form for each prescription and does not think the Board can jeopardize the practice of pharmacy to make it easier for doctors. President Jones stated that he does not think the Board needs to strike the whole rule as it has some merit. He asked if a verbal approval work would work if they were able to document this? Mr. Miller stated as long as there is a way to document it. Director Troughton stated that GDNA would treat that just as it would a phoned in prescription. He added that the cream issue is exactly what it being done where the patients are being contacted directly. He stated GDNA would need the documentation so it can contact the patient. President Jones stated that the Board can change the rule to say verbal or electronic means in an emergency situation. President Jones directed Ms. Harris and Mr. Faulk to review the rule and come up with the appropriate language.

### **Georgia Drugs and Narcotics Agency – Dennis Troughton**

Director Troughton reported that GDNA has received 297 complaints and conducted 1,587 investigations this year to date. He reported that GDNA has conducted several inspections for the Veterinarians. He stated there was a variety of ways they were keeping the records. He added that the inspections were done for educational purposes. He stated GDNA will share the results with the Department of Agriculture and the Georgia Veterinary Medical Association.

Director Troughton informed the Board that he has been asked to speak at several conferences. One is the FBI Citizens Academy Alumni Association and the FBI Atlanta field office are holding a forum on the opioid crisis in Georgia. The second is The United States Attorney’s Office for the Middle District of Georgia and the Georgia Emergency Management and Homeland Security Agency. He stated that when he speaks he is doing so as the Director of GDNA who works for the Board, not the Board itself.

**Attorney General’s Report – Max Changus**

Mr. Changus reported that he will be speaking before the Georgia Association of Healthcare Attorneys on May 3<sup>rd</sup> regarding opioids. He stated he will be there as a representative of the Attorney General’s office and will try not to render opinions.

**Executive Director’s Report – Tanja Battle**

Continuing Education Report: Report presented. Mike Faulk made a motion to ratify the below continuing education programs approved since the previous meeting. Lisa Harris seconded and the Board voted unanimously in favor of the motion.

Date of Program	Hours	Sponsoring Group	Program Title	CE Code
05/22/18	1	Kaiser Permanente	Closing Gaps in the Medicare Population: Statin Use in Persons with Diabetes	2018-0003
05/22/18	1	N/A	The Resilient Pharmacist - Focus on Burnout	2018-0004

Biosimilar products list link to FDA website: Ms. Battle stated section (8) of Rule 480-51-.02 Substituting Interchangeable Biological Products states *“A link for the current list of all biological products determined by the FDA to be interchangeable with a specific biological product is available on the Board’s website.”* However, Ms. Battle and Director Troughton have not been able to find the list and are not able to comply with the rule.

Hospice Emergency Drug Kits: The Board discussed correspondence received requesting clarification regarding hospice emergency drug kits. Specifically, the correspondence asks is the Home Care Hospice eligible to have an emergency kit in their office and can the patient’s nurse enter into the office, remove drugs, and deliver them to the Hospice patient? After further discussion, the Board stated there is nothing in the law or rules that would allow this to occur.

Ms. Battle discussed the State Treasury’s policy regarding convenience fees for credit card transactions. She stated she and staff are currently assessing contracts with various vendors that can support such. She wanted to share this as information to keep the Board updated as it will impact licensees in the future. She will continue to update as information regarding implementation becomes available.

**Legal Services – Kimberly Emm**

Change in Ownership: Ms. Emm discussed changes in ownership. She stated the owner’s inquiry is related to whether or not there is a percentage of stock transfer that triggers a new application. Ms. Battle added that the board office receives this question a lot. She stated that currently, if there is a stock change, the Board requires a written notice on letterhead, and if appropriate, an updated personnel certification form. Mr. Changus stated he felt it is time to try and rewrite the language as there can be various interpretations. Ms. Battle added that what the rule says is the original license is null and void once the sale is final. Mr. Changus responded by stating if one submits an application the Board will not void the original license until the new license is issued, but the rule is not written perfectly and some people get caught in a situation where there is no valid license. Mr. Miller stated the problem is if the Board requires the facility to obtain a new license number. Once that is done, they will then have to obtain a new DEA number and reapply every contract with a 3<sup>rd</sup> party payer. He stated if the Board can

transfer the license number to the new entity, if it is a stock transfer, there ought to be a way for people to move in and out. Ms. Battle responded by stating that is what we are currently doing. Jim Bracewell made a motion to direct Mr. Changus to review Rule 480-6-.01 Pharmacy Licenses and report back to the Board. Laird Miller seconded and the Board voted unanimously in favor of the motion.

### **Miscellaneous**

The Board discussed changes that need to be made to Rule 480-7B-.03 Designated Representatives for DME Suppliers. Ms. Emm will make the changes and forward to the Board later in the meeting for review.

Dangerous Drugs List: Director Troughton reported that he submitted two drugs, sodium chloride injection for catheter flush and triamcinolone acetonide nasal spray, to be removed from the dangerous drugs list. Ms. Emm will forward the two rules to the Board later in the meeting for review.

Director Troughton introduced Ms. Carla Leary to the Board. President Jones welcomed Ms. Leary and stated how much the Board appreciated all of her hard work.

Mike Faulk made a motion and Lisa Harris seconded, and the Board voted to enter into **Executive Session** in accordance with O.C.G.A. § 43-1-19(h)(2) and § 43-1-2(k) to deliberate and to receive information on applications, investigative reports and the Assistant Attorney General's report. Voting in favor of the motion were those present who included Vicki Arnold, Jim Bracewell, Mike Faulk, Lisa Harris, Chris Jones, and Laird Miller.

## **Executive Session**

### **Appearances**

- J.D.S.
- E.A.S.

### **Application**

- N.R.I.

### **Georgia Drugs and Narcotics Agency – Dennis Troughton**

- GDNA Case #T32443
- GDNA Case #T32458
- G.H.M.S.
- Animal Shelter Inspections

### **Cognizant's Report – Chris Jones**

- GDNA Case # T-32321
- GDNA Case # T-32494
- GDNA Case # T-32480
- GDNA Case # T-32440
- GDNA Case # B-32336
- GDNA Case # B-32452
- GDNA Case # B-32396
- GDNA Case # B-32425
- GDNA Case # B-32412
- GDNA Case # A-32466
- GDNA Case # B-32450

- GDNA Case # B-32391
- GDNA Case # B-32430
- GDNA Case # A-32475
- GDNA Case # B-32441
- GDNA Case # A-32461
- GDNA Case # B-32492

**Attorney General's Report – Max Changus**

Mr. Changus discussed the following cases:

- D.S.P.
- B.R.I.S.
- S.G.
- C.P.
- P.P.
- P.P.S./J.C.

Mr. Changus presented the following consent orders for acceptance:

- P.F.Q.
- A.R.W.
- A.P.B.
- C.V.S.P.
- T.D.
- T.W.T.
- C.P.
- W.P.D.
- T.K.C.
- W.D.
- G.W.M.T.
- C.P.
- C.V.S.P.
- M.D.K.
- A.S.D.

**Executive Director's Report – Tanja Battle**

No report.

**Legal Services – Kimberly Emm**

- C.V.S.P.
- S.P.

**Applications**

- A.L.L.
- A.D.G.
- A.S.A.
- K.N.A.
- C.M.S.
- K.E.G.
- A.N.P.
- C.L.R.

- T.A.C.
- L.M.P.
- R.B.T.
- R.L.B.
- W.B.D.
- A.S.B.
- N.R.P.
- R.A.W.
- S.M.K.
- J.W.R.
- C.W.J.
- R.A.B.
- M.R.M.
- A.M.M.

### **Correspondences/Requests**

- A.R.W.P.
- C.V.S.S.
- E.P.C.
- E.H.M.
- C.P.
- A.P.S.P.
- B.C.F.
- F.S.M.P.I.
- H.W.
- M.P.
- MV.P.S.
- M.V.S.P.
- M.V.S.P.
- O.R.
- R.U.P.
- V.R.
- W.P.I.
- W.P.N.
- C.D.S.
- M.M.F.
- D.L.S.S.
- A.H.G.I.
- A.P.I.
- D.M.T.
- D.L.G.
- P.J.M.
- J.Y.C.
- R.K.
- J.W.T
- C.L.H.
- J.F.C.
- M.C.F.



- C.M.H.
- K.P.R.P.
- M.L.M.
- R.L.D.
- T.A.C.
- Y.H.T.
- G.R.J.
- C.P.
- J.D.R.
- E.R.

No votes were taken in Executive Session. President Jones declared the meeting back in Open Session.

### Open Session

The Board discussed adding an extra meeting date in May. Jim Bracewell made a motion for May 17, 2018 to be an additional meeting date to conduct Board business. Laird Miller seconded and the Board voted unanimously in favor of the motion.

#### **Miscellaneous**

Mr. Miller brought up a concern regarding the rule proposed through the Department of Public Health, Rule 511-2-8, and how it is to be implemented in conjunction with what already exists in the Board of Pharmacy's rules. It was suggested that this subject be further discussed at the May meeting.

Discussion was held by the Board regarding a pamphlet Mr. Faulk presented concerning a product containing THC being sold in Georgia. Director Troughton stated if it is a product containing such in an amount under 5% that it is legal. Director Troughton stated that he does not know what authority he has other than to buy it and test it as the only way to know if should not be sold is to retrieve samples. Mr. Miller stated that the Board is interested in what the products have in them and if it is something that causes concern, a public advisory could be sent out regarding such. Discussion ensued regarding concerns that have arisen in other states regarding these products and what the Board needs to consider going forward.

President Jones reported that he recently attended an opioid conference. He has requested the GBI to look at toxicology reports to see if Gabapentin is a problem.

Mr. Bracewell stated the Board has previously discussed what information is being put on prescriptions, such as advertisements. Mr. Bracewell suggested that this could be a topic for the extended meeting in May.

Vicki Arnold made a motion to post Rule 480-34-.13 Triamcinolone Acetonide Nasal Spray, Rule 480-34-.14 Sodium Chloride Injection for Catheter Flush, and Rule 480-7B-.03 Designated Representatives for DME Suppliers. Mike Faulk seconded and the Board voted unanimously in favor of the motion.

#### **Rule 480-34-.13 Triamcinolone Acetonide Nasal Spray**

(1) This rule was adopted to protect the health, safety, and welfare of the public. Triamcinolone acetonide nasal spray 55mcg per spray or less, is hereby deleted from the Official Code of Georgia Annotated (O.C.G.A.) § 16-13-71(b)(976).

(2) This rule is based on the following findings of the Board:

(a) that triamcinolone acetonide nasal spray 55mcg per spray or less does not have a high potential for abuse;

(b) that the Board has considered the scientific evidence of its pharmacological effects; the state of current scientific knowledge regarding the drug; the history and current pattern of abuse; the scope, duration, and significance of abuse; the potential of the drug to produce psychic or physiological dependence liability; and

(c) that the drug, when in nasal spray form of 55mcg per spray or less has been approved for non-prescription status by the Federal Food and Drug Administration.

#### **Rule 480-34-.14 Sodium Chloride Injection for Catheter Flush**

(1) This rule was adopted to protect the health, safety, and welfare of the public. Sodium chloride injection in quantities of 10cc or less, when used as a catheter flush solution to act by physically occupying space within a catheter and exerting pressure on the patient's circulating blood, is hereby deleted from Official Code of Georgia Annotated (O.C.G.A.) § 16-13-71(b)(867).

(2) This rule is based on the following findings of the Board:

(a) that sodium chloride injection in quantities of 10cc or less does not have a high potential for abuse;

(b) that the Board has considered the scientific evidence of its pharmacological effects, the state of current scientific knowledge regarding the drug, the history and current pattern of abuse, the scope, duration, and significance of abuse, the potential of the drug to produce psychic or physiological dependence liability; and

(c) that the Federal Food and Drug Administration concluded that sodium chloride injection (saline injection or flush), when used as a catheter flush solution and acting in this manner, this solution meets the definition of a device in that it affects the structure or function of the body, and does not achieve its primary intended purposes through chemical or metabolic action.

#### **Rule 480-7B-.03 Designated Representatives for DME Suppliers.**

(1) **Requirement for Designated Representatives.** The Board shall only issue a license to a DME supplier if a qualified individual has been approved as a designated representative for the DME supplier. The designated representative will provide sufficient and qualified supervision of the DME supplier's place of business, ensuring compliance with all state and federal laws and regulations. The designated representative shall ensure the protection of the public health and safety in the handling, storage, warehousing, distribution, and shipment of durable medical equipment in the DME supplier's place of business. Where operations are conducted at more than one licensed place of business by a DME supplier, each licensed place of business shall have at least one designated representative present.

(2) **Qualifications of Designated Representatives.** In order to serve as a designated representative, an individual shall:

(a) Be at least 18 years of age;

(b) Submit a Board approved personnel certification form as part of the DME supplier's application to the Board;

(c) Attest to the knowledge and understanding of applicable state and federal laws and regulations relating to the distribution of durable medical equipment, knowledge and understanding of quality control systems, and knowledge and understanding of the United States Pharmacopeia of federal Food and Drug Administration standards relating to the safe storage, handling, and transport of durable medical equipment;

(d) Consent to provide the necessary information to conduct, and pay for a background check to be conducted by the Board, its agent or a firm or firms approved by the Board, which background check will include a criminal history, driver license history and other information as the Board deems necessary, and will authorize the Board and the Georgia Drugs and Narcotics Agency to receive the results; and

(e) If the designated representative is a licensed pharmacist, provide the state(s) of licensure, license number(s), and license status(es) of said license(s).

(3) Notice to Designated Representative. Any notice made to a DME supplier licensee shall be made to the designated representative on record with the Board. If notices are returned as undeliverable or unclaimed, service shall be made on the Executive Director, and any disciplinary proceedings shall proceed, or if a final decision, the decision shall become effective.

A motion was made by Jim Bracewell, seconded by Laird Miller, and the Board voted that the formulation and adoption of these proposed rules does not impose excessive regulatory cost on any licensee and any cost to comply with the proposed rules cannot be reduced by a less expensive alternative that fully accomplishes the objectives of the relevant code sections.

In the same motion, the Board also voted that it is not legal or feasible to meet the objectives of the relevant code sections to adopt or implement differing actions for businesses as listed at O.C.G.A. § 50-13-4(a)(3)(A), (B), (C) and (D). The formulation and adoption of these proposed rules will impact every licensee in the same manner, and each licensee is independently licensed, owned and operated and dominant in the field of pharmacy.

Laird Miller made a motion for the Board to take the following actions:

### Appearances

- |          |                                  |   |
|----------|----------------------------------|---|
| • J.D.S. | Request to discuss reinstatement | Table pending receipt of additional information |
| • E.A.S. | Request to discuss reinstatement | Refer to the Department of Law                  |

### Application

- |          |                            |   |
|----------|----------------------------|---|
| • N.R.I. | Denied Researcher Pharmacy | Overtake denial and approve application |
|----------|----------------------------|---|

### Georgia Drugs and Narcotics Agency – Dennis Troughton

- |                              |  |
|------------------------------|--|
| • GDNA Case #T32443          | Accept Voluntary Surrender   |
| • GDNA Case #T32458          | Accept Voluntary Surrender   |
| • G.H.M.S.                   | Table pending receipt of additional information  |
| • Animal Shelter Inspections | Approved to release information to the Georgia Board of Veterinary Medicine, Georgia Veterinary Medical Association, and the Georgia Department of Agriculture |

### Cognizant's Report – Chris Jones

- |                       |   |
|-----------------------|---|
| • GDNA Case # T-32321 | Revoke Technician Registration                              |
| • GDNA Case # T-32494 | Revoke Technician Registration                              |
| • GDNA Case # T-32480 | Accept Voluntary Surrender                                  |
| • GDNA Case # T-32440 | Revoke Technician Registration                              |
| • GDNA Case # B-32336 | Close with no action  |
| • GDNA Case # B-32452 | Misfill Policy #1   |
| • GDNA Case # B-32396 | Misfill Policy #1 to the RPh; Letter of concern to the tech |
| • GDNA Case # B-32425 | Refer to the Department of Law                              |
| • GDNA Case # B-32412 | Close with a letter of concern                              |
| • GDNA Case # A-32466 | Schedule Investigative Interview                            |
| • GDNA Case # B-32450 | Close with no action  |
| • GDNA Case # B-32391 | Misfill Policy #1   |
| • GDNA Case # B-32430 | Misfill Policy #1   |
| • GDNA Case # A-32475 | Refer to the Department of Law                              |

- GDNA Case # B-32441 Close with no action
- GDNA Case # A-32461 Refer to the Department of Law
- GDNA Case # B-32492 Schedule Investigative Interview

**Attorney General’s Report – Max Changus**

Mr. Changus discussed the following cases:

- D.S.P. Close case
- B.R.I.S. Close case
- S.G. Counterproposal denied
- C.P. Counterproposal denied
- P.P. Counterproposal denied
- P.P.S./J.C. Update provided

Mr. Changus presented the following consent orders for acceptance:

- P.F.Q. Private Consent Order accepted
- AllianceRx Walgreens Prime Public Consent Order accepted
- A.P.B. Private Consent Order accepted
- C.V.S.P. Private Consent Order accepted
- T.D. Private Consent Order accepted
- T.W.T. Private Consent Order accepted
- C.P. Private Consent Order accepted
- White’s Pharmacy of Dalton Public Consent Order accepted
- T.K.C. Private Consent Order accepted
- Wrens Drug Public Consent Order accepted
- Geoffrey W.M. Turner Public Consent Order accepted
- C.P. Private Consent Order accepted
- C.V.S. #7665 Public Consent Order accepted
- M.D.K. Private Consent Order accepted
- Aaron S. Davis Public Consent Order accepted

**Executive Director’s Report – Tanja Battle**

No report.

**Legal Services – Kimberly Emm**

- C.V.S.P. Open Records Request Denied Request
- S.P. Open Records Request Denied Request

**Applications**

- A.L.L. Pharmacy Technician Denied registration
- A.D.G. Pharmacy Technician Denied registration
- Adaeja S. Alexander Pharmacy Technician Approved for registration
- Kemi N. Ashimi Pharmacy Technician Approved for registration
- C. M. Simonds Pharmacy Technician Approved for registration
- K.E.G. Pharmacy Technician Denied registration
- Ashley N. Parkman Pharmacy Technician Approved for registration
- Chrisma L. Roberts Pharmacy Technician Approved for registration
- Tyra A. Camper Pharmacy Technician Approved for registration
- Larissa M. Pina Pharmacy Technician Approved for registration
- Ryan B. Tucker Pharmacy Technician Approved for registration

- Robin L. Barron Pharmacist Interns Approved application
- W.B.D. Pharmacist Interns Table pending receipt of additional information
- A.S.B. Pharmacist Exam Approved to sit for the exam
- N.R.P. Pharmacist Exam Approved to sit for the exam
- R.A.W. Pharmacist Exam Approved to sit for the exam
- S.M.K. Pharmacist Reciprocity Approved to sit for the exam
- J.W.R. Pharmacist Reciprocity Approved to sit for the exam
- Clarence W. Jaggard Pharmacist Reinstatement Approved application
- R.A.B. Pharmacist Reinstatement Table pending receipt of additional information
- M.R.M. Pharmacist Exam Approved to sit for the exam
- Anne M. Misher Pharmacist Cert of DTM Approved application

### Correspondences/Requests

- A.R.W.P. Notice of Discipline No action
- C.V.S.S. Notice of Discipline No action
- E.P.C. Notice of Discipline No action
- E.H.M. Notice of Discipline No action
- C.P. Notice of Discipline No action
- A.P.S.P. Notice of Discipline No action
- B.C.F. Notice of Discipline No action
- F.S.M.P.I. Notice of Discipline No action
- H.W. Notice of Discipline No action
- M.P. Notice of Discipline No action
- MV.P.S. Notice of Discipline No action
- M.V.S.P. Notice of Discipline No action
- M.V.S.P. Notice of Discipline No action
- O.R. Notice of Discipline No action
- R.U.P. Notice of Discipline No action
- V.R. Notice of Discipline No action
- W.P.I. Notice of Discipline No action
- W.P.N. Notice of Discipline No action
- C.D.S. Notice of Discipline Table pending receipt of additional information
- M.M.F. Notice of Discipline No action
- D.L.S.S. Notice of Discipline No action
- A.H.G.I. Notice of Discipline Refer to the Department of Law
- A.P.I. Correspondence No action
- D.M.T. Request to terminate consent order Denied request/extend probation by 1 year
- D.L.G. Request to terminate consent order Approved request effective 05/16/2018
- P.J.M. Request to terminate consent order Approved request
- J.Y.C. Request to terminate probation Approved request effective 05/12/2018
- R.K. Request to terminate probation Approved request
- J.W.T. Request to lift supervised practice Approved request

- C.L.H. Request to lift PIC restriction Approved request
- J.F.C. Request to lift supervised practice Schedule to meet with the Board
- M.C.F. Request to terminate probation Approved request
- C.M.H. Coursework submission Approved
- K.P.R.P. Request to maintain current retail pharmacy license Table pending receipt of additional information
- M.L.M. Request to take NAPLEX a 4<sup>th</sup> time Denied request
- R.L.D. Request to take NAPLEX a 4<sup>th</sup> time Denied request
- T.A.C. Appealing denial of request to take NAPLEX a 4<sup>th</sup> time/Request for a temporary intern license Denied requests
- Y.H.T. Request to take MPJE a 4<sup>th</sup> time Approved request
- G.R.J. Appearance request Approved request
- C.P. Request for approval of plans for drive thru Approved request
- J.D.R. Request for extension of MPJE score Approved request
- E.R. Records request from the Georgia Board of Nursing Approved request

Lisa Harris seconded and the Board voted in favor of the motion, with the exception of Chris Jones, who recused himself from the vote regarding GDNA Case #B-32452.

There being no further business to discuss, the meeting was adjourned at 3:01 p.m.

The next meeting of the Georgia Board of Pharmacy is scheduled for Wednesday, May 16, 2018 at 9:00 a.m. at the Department of Community Health's office located at 2 Peachtree Street, N.W., 5<sup>th</sup> Floor, Atlanta, GA 30303.

Minutes recorded by Brandi Howell, Business Support Analyst I  
 Minutes edited by Tanja D. Battle, Executive Director